1. Preoperative Low Creatine Kinase as a Poor Prognostic Factor in Patients with Colorectal Cancer.
- Author
-
Ushigome M, Shimada H, Kaneko T, Miura Y, Yoshida K, Suzuki T, Kagami S, Kurihara A, and Funahashi K
- Subjects
- Humans, Female, Male, Aged, Prognosis, Middle Aged, Neoplasm Recurrence, Local blood, Neoplasm Recurrence, Local pathology, Neoplasm Recurrence, Local epidemiology, Neoplasm Recurrence, Local diagnosis, Aged, 80 and over, Preoperative Period, Adult, Retrospective Studies, Neoplasm Staging, Risk Factors, Carcinoembryonic Antigen blood, Colorectal Neoplasms mortality, Colorectal Neoplasms blood, Colorectal Neoplasms pathology, Colorectal Neoplasms surgery, Creatine Kinase blood, Biomarkers, Tumor blood
- Abstract
Purpose: This study aimed to evaluate the clinicopathological and prognostic significance of preoperative serum creatine kinase (CK) levels in colorectal cancer., Methods: This study analyzed 1169 patients with colorectal cancer at stages 0 (n = 35), I (n = 301), II (n = 456), III (n = 339), and IV (n = 38). The CK cut-off value was 52 U/L to predict recurrence based on receiver operative characteristics curve. Clinicopathological factors were compared between the low (< 52 U/L) and high CK groups (≥ 52 U/L). The multivariate analysis evaluated relapse-free survival (RFS) and overall survival (OS) following CK status., Results: The female sex, elderly age (≥ 75), deep tumor (pT4), and carcinoembryonic antigen (+) were independently associated with low CK status. The recurrent rate was significantly higher in the low CK group than in the high CK group (19.1% vs. 11.7%, p < 0.001). Elderly age, pT4, pN (+), preoperative carbohydrate antigen (CA) 19-9 (+), and low CK status were independent risk factors for RFS. Elderly age, pT4, pN (+), preoperative CA19-9 (+), and low CK status were independent risk factors for OS., Conclusion: Preoperative low CK status was associated with deep tumors and was a poor prognostic factor in patients with colorectal cancer., (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF